This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • MRI characteristics of NMO, MOG and MS-related ON

MRI characteristics of NMO, MOG and MS-related ON
Reviewed by Su Young

3 June 2021 | Su Young | EYE - Neuro-ophthalmology | MRI, Optic nerve, multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody disease (MOG-AD), neuromyelitis optica (NMO), optic neuritis
Share This

This review article examined differences of MRI appearances that can help clinicians assess and manage these important neuro-ophthalmic disorders. It also examined the role of optic nerve MRI as a prognostic indicator in acute optic neuritis (ON). The major findings of this review are summarised as follows: 1) Unilateral vs. bilateral ON: Neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein (MOG) have a wide range of reports that vary from no reported cases to over 80% of ON cases being bilateral. However, both NMO and MOG appear to have a higher incidence of bilateral ON when compared to multiple sclerosis (MS) or ‘idiopathic’ ON, with the highest incidence reported as 23%. 2) Morphological appearance of the optic nerve on MRI: Clinical or radiographic appearance of optic nerve swelling may be more severe in MOG ON than other types of ON, as noted in three of five studies reporting optic nerve swelling secondary to MOG ON. 3) Location and length of lesions: Chiasmal involvement was noted in a majority of NMO patients (60-75%) in three studies while a range from 11% to 48% was noted in other studies. In contrast, chiasmal involvement in MOG patients was less common, ranging from 5% to 17% in eight reports and up to 21-25% according to two studies. Chiasmal involvement was uncommon in MS patients with the majority of studies finding involvement ranging from 0% to 15% except for one study with 33% involvement. Optic tract involvement was uncommon in all groups with NMO being the most affected at 7-18%, with one study showing 42%, compared to MOG patients with 2-13% and 13% in two MS studies. NMO was more likely to be associated with longitudinally extensive optic nerve lesions (LEON), which in contrast, is uncommonly found in MS. Similarly, MOG patients characteristically have LEON (in the range of 23-88%) with three reports showing significantly longer segments of optic nerve involvement in MOG when compared to NMO. 4) MRI appearance as a prognostic indicator: Intercanalicular location and more extensive lesions were associated with poorer visual outcomes in two studies. One study found that NMO had the worst visual prognosis compared to MOG and MS, and that longer optic nerve lesions in NMO patients were the strongest predictor of poor final visual acuity.

MRI characteristics of NMO, MOG and MS related optic neuritis.
Winter A, Chwalisz B.
SEMINARS IN OPHTHALMOLOGY
2020;35(7-8):333-42.
Share This
Su Young
CONTRIBUTOR
Su Young

Tennent Institute of Ophthalmology, NHS Greater Glasgow and Clyde, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency